Predilife（ALPRE）株式概要プレディライフS.A.は医療技術と数理モデルを開発・販売している。 詳細ALPRE ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析過去5年間で収益は年間12.9%減少しました。 マイナスの株主資本 収益が 100 万ドル未満 ( €728K )最新の財務報告は6か月以上前のものである +1 さらなるリスクすべてのリスクチェックを見るALPRE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€2.6029.5% 割安 内在価値ディスカウントEst. Revenue$PastFuture-5m4m2016201920222025202620282031Revenue €4.2mEarnings €782.7kAdvancedSet Fair ValueView all narrativesPredilife S.A. 競合他社AtonSymbol: ENXTPA:ALTAOMarket cap: €11.1mPlant Advanced TechnologiesSymbol: ENXTPA:ALPATMarket cap: €7.6mNicoxSymbol: ENXTPA:ALCOXMarket cap: €33.0mPoxelSymbol: ENXTPA:POXELMarket cap: €11.9m価格と性能株価の高値、安値、推移の概要Predilife過去の株価現在の株価€2.6052週高値€4.0052週安値€2.42ベータ0.271ヶ月の変化-12.75%3ヶ月変化-17.20%1年変化-33.33%3年間の変化-58.40%5年間の変化-60.61%IPOからの変化-72.04%最新ニュースお知らせ • May 27Predilife S.A., Annual General Meeting, Jun 30, 2026Predilife S.A., Annual General Meeting, Jun 30, 2026. Location: 1 rue royale bureaux de la colline, saint cloud FranceNew Risk • May 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$856k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€11.3m market cap, or US$13.2m).New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$854k). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€13.0m market cap, or US$15.2m).Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€13m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (€493k revenue, or US$577k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€12.1m market cap, or US$14.2m).Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.最新情報をもっと見るRecent updatesお知らせ • May 27Predilife S.A., Annual General Meeting, Jun 30, 2026Predilife S.A., Annual General Meeting, Jun 30, 2026. Location: 1 rue royale bureaux de la colline, saint cloud FranceNew Risk • May 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$856k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€11.3m market cap, or US$13.2m).New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$854k). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€13.0m market cap, or US$15.2m).Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€13m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (€493k revenue, or US$577k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€12.1m market cap, or US$14.2m).Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.お知らせ • May 20Predilife S.A., Annual General Meeting, Jun 23, 2025Predilife S.A., Annual General Meeting, Jun 23, 2025. Location: 1 rue royale bureaux de la colline, batiment b 9e etage, saint cloud FranceNew Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€3.5m). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (€301k revenue, or US$334k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€14.0m market cap, or US$15.6m).New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.3m free cash flow). Share price has been highly volatile over the past 3 months (62% average weekly change). Negative equity (-€9.1m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€318k revenue, or US$345k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€22.7m market cap, or US$24.6m).New Risk • Apr 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$332k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.2m market cap, or US$16.2m).New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$340k). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (€16.9m market cap, or US$18.4m).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 27Full year 2021 earnings releasedFull year 2021 results: Net loss: €3.41m (loss widened 52% from FY 2020).Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 29Full year 2020 earnings released: €0.64 loss per share (vs €0.71 loss in FY 2019)Full year 2020 results: Net loss: €2.25m (loss widened 7.1% from FY 2019).Is New 90 Day High Low • Jan 11New 90-day low: €6.85The company is down 4.0% from its price of €7.10 on 13 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 25% over the same period.Is New 90 Day High Low • Nov 06New 90-day high: €8.30The company is up 24% from its price of €6.70 on 07 August 2020. The French market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 15New 90-day high: €7.80The company is up 20% from its price of €6.50 on 17 July 2020. The French market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.株主還元ALPREFR BiotechsFR 市場7D-10.0%-19.4%-0.08%1Y-33.3%238.3%1.8%株主還元を見る業界別リターン: ALPRE過去 1 年間で238.3 % の収益を上げたFrench Biotechs業界を下回りました。リターン対市場: ALPREは、過去 1 年間で1.8 % のリターンを上げたFrench市場を下回りました。価格変動Is ALPRE's price volatile compared to industry and market?ALPRE volatilityALPRE Average Weekly Movement4.9%Biotechs Industry Average Movement9.6%Market Average Movement5.2%10% most volatile stocks in FR Market11.2%10% least volatile stocks in FR Market2.8%安定した株価: ALPRE 、 French市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: ALPREの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200427Stephane Ragusawww.predilife.comPredilife S.A.は医療技術と数理モデルを開発・販売している。同社は予防と乳房検診検査を提供している。同社の製品には、患者個人のリスクに基づいて乳がんの発症を予測する検査「MammoRisk」、乳房密度測定ソフトウェア「DenSeeMammo」、前立腺がんのリスクを予測する医療機器などがある。プレディライフ社は2004年に設立され、フランスのヴィルジュイフに本社を置いている。もっと見るPredilife S.A. 基礎のまとめPredilife の収益と売上を時価総額と比較するとどうか。ALPRE 基礎統計学時価総額€9.82m収益（TTM）-€3.80m売上高(TTM)€728.08k13.5xP/Sレシオ-2.6xPER（株価収益率ALPRE は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ALPRE 損益計算書（TTM）収益€728.08k売上原価€19.92k売上総利益€708.16kその他の費用€4.50m収益-€3.80m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）-1.00グロス・マージン97.26%純利益率-521.47%有利子負債／自己資本比率-32.6%ALPRE の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/07 02:29終値2026/06/05 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Predilife S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jean-Pierre LozaIn Extenso Financement & Marché
お知らせ • May 27Predilife S.A., Annual General Meeting, Jun 30, 2026Predilife S.A., Annual General Meeting, Jun 30, 2026. Location: 1 rue royale bureaux de la colline, saint cloud France
New Risk • May 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$856k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€11.3m market cap, or US$13.2m).
New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$854k). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€13.0m market cap, or US$15.2m).
Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).
New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€13m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (€493k revenue, or US$577k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€12.1m market cap, or US$14.2m).
Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.
お知らせ • May 27Predilife S.A., Annual General Meeting, Jun 30, 2026Predilife S.A., Annual General Meeting, Jun 30, 2026. Location: 1 rue royale bureaux de la colline, saint cloud France
New Risk • May 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$856k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€11.3m market cap, or US$13.2m).
New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$854k). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€13.0m market cap, or US$15.2m).
Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).
New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€13m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (€493k revenue, or US$577k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€12.1m market cap, or US$14.2m).
Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.
お知らせ • May 20Predilife S.A., Annual General Meeting, Jun 23, 2025Predilife S.A., Annual General Meeting, Jun 23, 2025. Location: 1 rue royale bureaux de la colline, batiment b 9e etage, saint cloud France
New Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€3.5m). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (€301k revenue, or US$334k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€14.0m market cap, or US$15.6m).
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.3m free cash flow). Share price has been highly volatile over the past 3 months (62% average weekly change). Negative equity (-€9.1m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€318k revenue, or US$345k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€22.7m market cap, or US$24.6m).
New Risk • Apr 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$332k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.2m market cap, or US$16.2m).
New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$340k). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (€16.9m market cap, or US$18.4m).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 27Full year 2021 earnings releasedFull year 2021 results: Net loss: €3.41m (loss widened 52% from FY 2020).
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 29Full year 2020 earnings released: €0.64 loss per share (vs €0.71 loss in FY 2019)Full year 2020 results: Net loss: €2.25m (loss widened 7.1% from FY 2019).
Is New 90 Day High Low • Jan 11New 90-day low: €6.85The company is down 4.0% from its price of €7.10 on 13 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 25% over the same period.
Is New 90 Day High Low • Nov 06New 90-day high: €8.30The company is up 24% from its price of €6.70 on 07 August 2020. The French market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 15New 90-day high: €7.80The company is up 20% from its price of €6.50 on 17 July 2020. The French market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
